Latrophilins as Downstream Effectors of Androgen Receptors including a Splice Variant, AR-V7, Induce Prostate Cancer Progression
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25137289 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Yuki Teramoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA. Hauptthemen laut MEDLINE: Receptors, Androgen, Prostatic Neoplasms, Disease Progression. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Latrophilins (LPHNs), a group of the G-protein–coupled receptor to which a spider venom latrotoxin (LTX) is known to bind, remain largely uncharacterized in neoplastic diseases. In the present study, we aimed to determine the role of LPHNs in the progression of prostate cancer. We assessed the actions of LPHNs, including LPHN1, LPHN2, and LPHN3, in human prostate cancer lines via their ligand (e.g., α-LTX, FLRT3) treatment or shRNA infection, as well as in surgical specimens. In androgen receptor (AR)-positive LNCaP/C4-2/22Rv1 cells, dihydrotestosterone considerably increased the expression levels of LPHNs, while chromatin immunoprecipitation assay revealed the binding of endogenous ARs, including AR-V7, to the promoter region of each LPHN. Treatment with α-LTX or FLRT3 resulted in induction in the cell viability and migration of both AR-positive and AR-negative lines. α-LTX and FLRT3 also enhanced the expression of Bcl-2 and phosphorylated forms of JAK2 and STAT3. Meanwhile, the knockdown of each LPHN showed opposite effects on all of those mediated by ligand treatment. Immunohistochemistry in radical prostatectomy specimens further showed the significantly elevated expression of each LPHN in prostate cancer, compared with adjacent normal-appearing prostate, which was associated with a significantly higher risk of postoperative biochemical recurrence in both univariate and multivariable settings. These findings indicate that LPHNs function as downstream effectors of ARs and promote the growth of androgen-sensitive, castration-resistant, or even AR-negative prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.
- James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA.
- Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA.
ORCID-Profile: Yuki Teramoto, Mohammad Amin Elahi Najafi, Takuro Goto, Hiroshi Miyamoto
Zitieren
APA
Teramoto, Y., Elahi Najafi, M. A., Matsukawa, T., Sharma, A., Goto, T., & Miyamoto, H. (2024). Latrophilins as Downstream Effectors of Androgen Receptors including a Splice Variant, AR-V7, Induce Prostate Cancer Progression. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137289
Vancouver
Teramoto Y, Elahi Najafi MA, Matsukawa T, Sharma A, Goto T, Miyamoto H. Latrophilins as Downstream Effectors of Androgen Receptors including a Splice Variant, AR-V7, Induce Prostate Cancer Progression. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137289
BibTeX
@article{Teramoto2024,
author = {Teramoto, Yuki and Elahi Najafi, Mohammad Amin and Matsukawa, Takuo and Sharma, Adhya and Goto, Takuro and Miyamoto, Hiroshi},
title = {Latrophilins as Downstream Effectors of Androgen Receptors including a Splice Variant, AR-V7, Induce Prostate Cancer Progression},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25137289}
}
EUVIMED